Patient enrollment for Synergy OIC drug trial complete

Patient enrollment in the 260-patient Phase 2 clinical trial evaluating Synergy Pharmaceuticals' (SGYP -5.7%) uroguanylin analog SP-333 as a treatment for opioid-induced constipation (OIC) is complete. The randomized double-blind study will compare the safety and efficacy of SP-333 versus placebo in patients taking opioid analgesics for chronic non-cancer pain for at least three months. The primary endpoint is the mean change from baseline in the number of spontaneous bowel movements during Week 4 of the Treatment Period.

Synergy intends to release top-line data from the trial in Q4.

Related tickers: (NKTR -5.2%) (AZN -2.1%) (CBST -0.8%) (SLXP -1.6%) (PGNX)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs